Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Total Non-current Liabilities

All obligations due after more than one year.

Crescent Biopharma, Inc.NASDAQ: CBIO

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities remains negative

Q1 FY2026 total non-current liabilities was $1.09M, compared with $0 a year earlier.

Context

  • Total non-current liabilities amounted to 0.5% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
  • Total non-current liabilities increased in 2 of the last 3 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.09M-9.8% QoQ
Last fiscal yearDec 2025
$1.21M-97.1% YoY
Year agoMar 2025
$0— since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-97.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
1.21M USD
Year-over-year change
-97.1%
4-year CAGR
+7.1%

Total Non-current Liabilities vs competitors

How CBIO compares with its peers on the latest reported figures

  • CBIO's Mar 2026 total non-current liabilities of $1.09M is the 8th highest of the 10 companies compared; the peer median is $11.55M.
  • Total non-current liabilities amounts to 0.5% of total assets for CBIO, versus a peer median of 4.1%.
CBIO Competitors Peer median
Total Non-current Liabilities for CBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZYMEZymeworks Inc.Sep 2026$756.7M +2052.0%-16.0%64.3%
RCUSArcus Biosciences, Inc.Jun 2026$262M -17.1%-17.6%28.4%
MGNXMacroGenics, Inc.Mar 2026$100.74M +11.9%+16.9%46.2%
CGENCompugen Ltd.Mar 2026$28.47M -23.8%+90.4%19.5%
CLDXCelldex Therapeutics, Inc.Sep 2026$11.55M +219.7%-15.2%1.6%
CMPXCompass Therapeutics, Inc.Mar 2026$8.42M +34.2%+68.7%4.1%
CTMXCytomX Therapeutics, Inc.Mar 2026$5.39M -76.8%-68.7%1.5%
CBIOCrescent Biopharma, Inc.Mar 2026$1.09M ——0.5%
NBPNovaBridge BiosciencesDec 2025$384.13K -98.3%-90.2%1.0%
CNTXContext Therapeutics Inc.Mar 2026$122.37K +48.1%—0.2%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) $11.55M+11.9%-15.6%4.1%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents90.25M47.87M41.79M34.77M213.19M
Short-term Investments00000
Net Receivables1.35K144.02K175.82K018M
Inventory00000
Other Current Assets00038K1.28M
Total Current Assets90.79M50.71M43.79M34.8M236.66M
Property, Plant & Equipment (Net)1.95M751.17K767.83K02.32M
Goodwill00000
Intangible Assets00004.73M
Long-term Investments0000107K
Tax Assets00000
Other Non-current Assets1.61M344.71K757.91K813K(3.51M)
Total Non-current Assets3.56M1.1M1.53M813K3.64M
Total Assets94.35M51.81M45.32M35.62M240.29M
Account Payables2.11M970.19K868.12K107K10M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00004.16M
Other Current Liabilities2.5M2.97M2.96M76K16.36M
Total Current Liabilities11.82M8.88M6.84M9.61M36.07M
Long-term Debt00037.48M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0004M0
Total Non-current Liabilities918.61K066.84K41.48M1.21M
Total Liabilities12.74M8.88M6.9M51.1M37.28M
Common Stock52.31K54.38K64.39K1K28K
Retained Earnings(372.9M)(419.59M)(456.49M)(17.87M)(171.81M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity81.6M42.93M38.41M(15.48M)203.01M
Total Debt1.92M918.56K808.4K37.48M1.64M
Net Debt(88.33M)(46.95M)(40.98M)2.72M(211.55M)

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.